Deregulated glucose metabolism fulfi lls the energetic and biosynthetic requirements for tumor growth driven by oncogenes. Because inhibition of oncogenic BRAF causes profound reductions in glucose uptake and a strong clinical benefi t in BRAF -mutant melanoma, we examined the role of energy metabolism in responses to BRAF inhibition. We observed pronounced and consistent decreases in glycolytic activity in BRAF -mutant melanoma cells. Moreover, we identifi ed a network of BRAF-regulated transcription factors that control glycolysis in melanoma cells. Remarkably , this network of transcription factors, including hypoxia-inducible factor-1α, MYC, and MONDOA (MLXIP), drives glycolysis downstream of BRAF V600 , is critical for responses to BRAF inhibition, and is modulated by BRAF inhibition in clinical melanoma specimens. Furthermore, we show that concurrent inhibition of BRAF and glycolysis induces cell death in BRAF inhibitor (BRAFi)-resistant melanoma cells. Thus, we provide a proof-of-principle for treatment of melanoma with combinations of BRAFis and glycolysis inhibitors.
INTRODUCTION
Increased glycolysis in tumor cells compared with normal tissues is observed in most cancers and supports the increased energetic and biosynthetic demands of tumor cells ( 1 ) . Control of glycolysis by oncogenes and tumor suppressors, such as AKT, TP53, and MYC, is believed to contribute to their tumorigenic activities ( 2 ) . Treatment of AKT-driven tumor cells or tumors with PI3K/AKT/MTOR inhibitors, such as PF04691502, BEZ235, and ridaforolimus, suppresses glucose uptake and tumor growth/cell survival (3) (4) (5) . Although the role of glucose metabolism in oncogene-driven tumorigenesis has been well characterized, it remains unclear whether regulation of glucose metabolism by oncogenes is important for tumor responses to oncogenetargeted therapy.
The development of therapies targeting BRAF in melanoma is a clear example of successful targeting of an oncogene for the treatment of cancer. Activating BRAF mutations, particularly the V600 amino acid substitution, have been identifi ed in approximately 50% of metastatic melanomas ( 6 ) , and BRAF V600 melanomas rely on RAF-MEK-ERK signaling for growth and survival ( 7 ) . BRAF V600 expression has been associated with increased glycolytic activity and cell surface glucose transporter 1 (GLUT1 or SLC2A1) expression in colorectal and thyroid cancer cells ( 8, 9 ) , indicating that glucose metabolism could be important for BRAF-driven tumorigenesis. Recently, RAF-MEK-ERK pathway inhibitors, including the BRAF inhibitors (BRAFi) vemurafenib (RG7204; PLX4032) and dabrafenib (GSK2118436), have been validated for treatment of BRAF V600 melanoma, with striking response rates in excess of 50% in patients diagnosed with BRAF V600 metastatic melanoma (10) (11) (12) (13) (14) . Importantly, BRAF V600 inhibition potently suppresses uptake of the radioactive glucose tracer 2[
18 F]fl uoro-2-deoxy-D -glucose (FDG) in BRAF V600 human melanoma cells and xenografts ( 15, 16 ) and in patients with BRAF V600 melanoma ( 10 , 17 , 18 ) , suggesting that inhibition of glycolysis by BRAF pathway inhibition could be important for clinical responses to BRAFi.
Here, we show that BRAF inhibition potently suppressed glycolysis independently of cell-cycle progression and cell death via suppression of hexokinase II (HK2) and GLUT1/3 expression in melanoma cells and clinical BRAF V600 melanomas biopsies. We also found that glucose metabolism is restored upon development of BRAFi resistance, a major challenge in the clinical management of BRAF V600 melanoma, and that this is overcome by combination with a glycolysis inhibitor. We used microarray experiments to elucidate the mechanisms by which RAF-MEK-ERK signaling promotes glycolysis. This led us to identify and validate a novel network of transcriptional regulators of glycolysis, composed of hypoxia-inducible factor-1α (HIF1A), MYC, and MONDOA, that are altered by BRAFi treatment and development of BRAFi resistance in BRAF V600 melanoma cells and BRAF V600 melanoma biopsies.
RESULTS
To determine the effect of RAF-MEK-ERK signaling on glucose metabolism in melanoma cells, a panel of BRAF WT and BRAF V600 human melanoma cells were treated with the 1A ) . Furthermore, the degree to which vemurafenib inhibited glucose uptake correlated signifi cantly with the degree of sensitivity to vemurafenib-mediated suppression of proliferation ( r 2 = 0.7355; P = 0.0002; Fig. 1B ) . Furthermore, we show that the degree of glycolysis suppression signifi cantly correlates with the degree of inhibition of the transcription of ERK (MAPK3/MAPK1) target genes described herein (Supplementary Fig. S1 ). This indicates that the degree of ERK pathway inhibition may correlate with the degree of glycolysis inhibition. Treatment with vemurafenib also suppressed lactate and ATP production in BRAF V600 but not BRAF WT cells ( Fig. 1C and  D ) , confi rming that BRAFi suppresses glycolytic fl ux. Importantly, inhibition of glycolysis by BRAFi was not a consequence of altered cell-cycle progression or apoptosis induction (Supplementary Fig. S2A-S2D ), indicating that BRAF V600 directly promotes glycolysis in human melanoma cells. We also examined glycolytic fl ux and oxidative phosphorylation (oxphos) determined by measurement of the extracellular acidifi cation rates (ECAR) and oxygen consumption rates (OCR), respectively, in melanoma cells ( Supplementary Fig. S3A-S3F ). This demonstrated signifi cant decreases in ECAR ( Fig. 1E ) and small decreases in OCR ( Fig. 1F ) in BRAF V600 cells. To investigate the molecular mechanisms underlying BRAF V600 -driven glycolysis, we examined the effect of BRAFi on glycolytic enzymes ( Supplementary Fig. S4 ). BRAFi increased pyruvate dehydrogenase (PDH) catalytic subunit E1α (PDHA1) phosphorylation at Ser293, which would correspond to decreased enzymatic activity and suppressed oxphos ( Fig. 1G ; ref. 19 ). Interestingly, suppression of HK2 protein expression and decreased membrane expression of GLUT1 and GLUT3 (the key GLUT isoforms expressed in human melanomas; ref. 20 ) was observed in BRAF V600 melanoma cells treated with vemurafenib ( Fig. 1G and H ) . These changes were associated with signifi cant reductions in mRNA expression of the genes encoding HK2, GLUT1, and GLUT3 ( HK2 , SLC2A1 , and SLC2A3 , respectively; Fig. 1I ), indicating that BRAF V600 -mediated glycolysis regulation occurs at a transcriptional level.
To examine the effect of BRAF inhibition on markers of glycolysis in a clinical context, we analyzed HK2 , SLC2A1 , and SLC2A3 mRNA expression in melanoma biopsies from patients diagnosed with BRAF V600 melanoma obtained before treatment (Pre), early on treatment (EOT) with a BRAFi (days [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , and after disease progression (Prog; Supplementary Table S1 ). In most cases, expression of the HK2 , SLC2A1 , and SLC2A3 genes signifi cantly decreased upon BRAFi treatment ( P < 0.05) and was signifi cantly restored upon development of drug resistance ( Fig. 1J and Supplementary Fig. S5A-S5F ). Biopsies from patients who experienced stable disease or a partial response to BRAFi [Response Evaluation Criteria in Solid Tumors (RECIST) criteria] demonstrated signifi cantly greater reductions in tumor SLC2A1 mRNA levels compared with patients who experienced disease progression ( Fig. 1K ; P = 0.04). This agrees with the potent suppression of FDG uptake in BRAF V600 melanomas after BRAFi therapy ( 10 , 17 , 18 ) . On the basis of these data, we hypothesized that melanoma cells require glycolysis for proliferation/survival. 3 H]-2DOG uptake by vemurafenib and proliferation IC 50 s for vemurafenib treatment. l -lactate production (C) and ATP production (D) were determined in vemurafenibtreated melanoma cells (expressed as percentage change; control vs. 3 μmol/L vemurafenib; 20 hours). ECAR (E) and OCR (F) in human melanoma cells (percentage of control) determined using a Seahorse XF24 Extracellular Flux Analyzer. G, effect of vemurafenib on protein expression in melanoma cells was determined by Western immunoblotting (control vs. 3 μmol/L vemurafenib; 20 hours) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. H, membrane versus cytoplasmic GLUT1 and GLUT3 expression in melanoma cells (control vs. 3 μmol/L vemurafenib; 20 hours). Na + K + -ATPase was used as a membrane-specifi c loading control. I, gene expression of SLC2A1 (GLUT1), SLC2A3 (GLUT3), and HK2 (control vs. 3 μmol/L vemurafenib; 20 hours) was determined by quantitative real-time PCR (qRT-PCR ). J, mRNA expression in melanoma biopsies. For all patients, RNA was extracted from fresh-frozen BRAF V600 melanoma biopsies obtained from patients pretreatment (Pre), early on dabrafenib (BRAFi) ± trametinib (MEK inhibitor), or vemurafenib treatment (BRAFi; EOT) and, in some cases, after disease progression (Prog). Data are included only for patients who showed stable disease or a partial response (RECIST criteria) EOT. Changes in gene expression were determined using an Illumina BeadStation (patients 1-7; Δ), Affymetrix Human Gene 1.0 ST Arrays (patient 8; ♦), or by RNAseq for patient 9 (¬). For all patients, data are expressed as the mean average signal intensity across all biopsies for an individual patient at each time point. K, change in SLC2A1 gene expression between baseline and EOT in responders [partial response (PR) or stable disease (SD)] versus nonresponders (progressive disease; PD) to BRAFi ± MEKi treatment. A, C and D, data represent mean ± SEM ( n = 3). *, P < 0.05. Data were analyzed using a one-way ANOVA coupled with a Tukey multiple comparison post hoc test. E and F, data represent mean ± SEM ( n = 5). *, P < 0.05. Data were analyzed using a one-way ANOVA coupled with a Tukey multiple comparison post hoc test. B , Pearson correlation, P < 0.001. I, data represent mean ± SEM ( n = 3). *, P < 0.05. Two-way ANOVA coupled with a Tukey post hoc test. G and H, images are representative of two independent experiments. J, data points represent mean data values across all biopsies from a single patient pretreatment, and lines represent individual patients. Data were analyzed using t tests coupled with a Wilcoxon matched pairs signed-rank test and P < 0.05 denotes a statistically signifi cant difference. K, lines represent mean fold-change in gene expression (EOT vs. Pre) and symbols represent individual patients. Data were analyzed using a t test coupled with a Mann-Whitney test, where P < 0.05 denotes a statistically signifi cant difference. 
RESEARCH BRIEF
Consistent with this hypothesis, inhibition of glycolysis via siRNA-mediated knockdown of HK2, GLUT1, or GLUT3 or glucose withdrawal suppressed the proliferation of human melanoma cell lines ( Supplementary Fig. S6A-S6D ).
Acquired resistance to BRAF inhibition occurs clinically after a median of 5 to 8 months ( 14 , 21 ) , and several mechanisms of resistance have been identifi ed, including activation of NRAS ( 22 ) . On the basis of the clinical importance of BRAFi resistance and the observation that HK2 , SLC2A1 , and SLC2A3 mRNA expression is restored in some patient tumors upon disease progression ( Fig. 1J ) , we interrogated the role of glycolysis in BRAFi resistance. We rendered BRAF with vemurafenib alone or in combination with the pyruvate mimetic dichloroacetate (DCA). DCA inhibits PDH kinase (PDK) isoforms that cause downstream reactivation of the catalytic subunit of PDH (PDHE1α), thereby suppressing glycolytic metabolism ( 19 ) . This combination was assessed using engineered NRAS Q61K -expressing cell lines, M249-AR4 cells that developed an NRAS mutation during long-term selection in vemurafenib and an early-passage cell line (M376) derived from a clinical melanoma specimen with acquired vemurafenib resistance that developed an NRAS mutation ( 22 ) . Inhibition of PDK using a concentration of DCA that almost completely suppresses PDHE1α phosphorylation produced 21.8% cell death in A375 BRAF V600 melanoma cells (Supplementary Fig. S7B and S7C ). However, combination treatment with vemurafenib + DCA induced apoptosis to a greater degree than with either agent alone ( Fig. 2F and Supplementary Fig. S7D ), concomitant with greater inhibition of lactate/ATP production ( Fig. 2G and Supplementary  Fig. S7E and S7F). We also observed a signifi cant, albeit less pronounced, enhancement of the effect of the MEK inhibitor PD0325901 (PD901) by DCA on vemurafenib-resistant melanoma cells, indicating that the extent of ERK inhibition is likely to be important for the enhancement produced by glycolysis inhibition (Supplementary Fig. S8 ).
Combination treatment of vemurafenib-resistant melanoma cells did not enhance the suppression of ERK or PDHE1α phosphorylation by vemurafenib or DCA alone, indicating that the interaction between these drugs does not result from enhancement of drug activity ( Fig. 2J and Supplementary Fig. S9A-S9D ). Furthermore, vemurafenib + DCA potently increased superoxide production and tetramethylrhodamineethylester (TMRE) staining (indicative of mitochondrial hyperpolarization) in vemurafenib-resistant cells ( Fig. 2K and Supplementary Fig. S7H ).
Initially, we examined the possible involvement of MTOR in glycolytic responses to BRAF inhibition, as MTOR complex 1 (mTORC1) activity has been shown to be important for responses to BRAF inhibition in melanoma ( 23 ) and may also be important for AKT-driven glycolysis. We found that after 2 hours of treatment with vemurafenib, ribosomal protein S6 phosphorylation was modestly suppressed, but 4EBP1 phosphorylation was unchanged. These observations could be explained by mTORC1-dependent regulation of S6 by ERK, although mTORC1-independent regulation of S6 by ERK has also been described ( 24 ) . After 24 hours of treatment, stronger inhibition of S6 and 4EBP1 phosphorylation occurred ( Supplementary Fig. S10 ). Because glucose uptake is maximally suppressed within 20 hours of vemurafenib treatment, and because signifi cant inhibition of GLUT1 and GLUT3 mRNA expression occurs within 4 hours of vemurafenib treatment ( Supplementary Fig. S10 ), it is unlikely that these late changes to mTORC1 activity contribute significantly to the regulation of glycolysis by vemurafenib. Previous work has also demonstrated that BRAF V600 regulates LKB1 (STK11)-AMPK (PRKA) pathway activity in melanoma cells ( 25 ) . Because this pathway is known to regulate energy metabolism, we examined its involvement in BRAF V600 -driven glycolysis. We did not observe consistent regulation of LKB1-AMPK signaling by vemurafenib in melanoma cells ( Supplementary Fig. S10 ). Thus, BRAF V600 -mediated regulation of glycolysis in melanoma cells occurs by an asyet-unidentifi ed mechanism. To investigate the mechanism by which BRAF V600 regulates glycolysis in melanoma, we conducted microarrays and used gene set enrichment analysis (GSEA) and candidate gene analysis to identify putative glycolysis-regulating BRAF targets.
Of the gene sets that were signifi cantly enriched in control versus vemurafenib-treated cells (Supplementary datasets S1 and S2), we identifi ed 15 MYC-regulated and four hypoxiaregulated gene sets, as well as three glycolysis-related gene sets ( Fig. 3A and Supplementary Table S2 ). Because c-Myc and HIF-1α (the key mediator of hypoxia-stimulated gene transcription) are established positive regulators of glucose metabolism ( 26, 27 ) , we posited that these are likely to be important for regulation of glycolysis by BRAF V600 . MONDOA, however, is a critical negative regulator of glucose uptake ( 28 ) . Although regulation of energy metabolism and the regulation of MONDOA activity by oncogenic signaling pathways are well defi ned ( 28 ) , the role of MONDOA in tumorigenesis has yet to be fully elucidated. Here, we describe signifi cant increases in expression of thioredoxin-interacting protein ( TXNIP ) and arrestin domain-containing 4 ( ARRDC4 ), two direct transcriptional targets of MONDOA ( 28 ) , in response to BRAF . F, mRNA expression in melanoma biopsies. For patients 1-7 (Δ), RNA was extracted from fresh-frozen BRAF V600 melanoma biopsies from patients pretreatment (Pre), early on dabrafenib therapy (On; 140-600 mg daily; biopsies taken between days 3-14), and after progression (Prog). Changes in gene expression were determined using an Illumina BeadStation (patients 1-7; Δ), Affymetrix Human Gene 1.0 ST Arrays (patient 8; ♦), or by RNAseq for patient 9 (¬). B-D, each data point represents mean ± SEM ( n = 3); *, P < 0.05. C, one-way ANOVA coupled with a Tukey post hoc test. D, data were analyzed using t tests. E, images are representative of two independent experiments. F, data points represent mean data values across all biopsies from a single patient pretreatment and lines represent individual patients. Data were analyzed using t tests coupled with a Wilcoxon matched pairs signed-rank test and P < 0.05 denotes a statistically signifi cant difference. G, lines represent mean fold-change in gene expression (EOT vs. Pre) and symbols represent individual patients. Data were analyzed using a t test coupled with a Mann-Whitney test, where P < 0.05 denotes a statistically signifi cant difference. IgG, immunoglobulin G; FDR, false discovery rate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. . To confi rm this, we performed chromatin immunoprecipitation assays to examine binding of MondoA to the TXNIP and ARRDC4 promoters and observed that vemurafenib treatment stimulated binding of MondoA to both the TXNIP and ARRDC4 promoters in vemurafenibsensitive A375-pBp ( Fig. 3C ) . Importantly, NRAS Q61K expression suppressed this effect, indicating tight regulation of MondoA promoter-binding activity by mutant BRAF.
We confi rmed that vemurafenib treatment increased TXNIP expression and decreased MYC and HIF-1α expression at the mRNA and protein levels in BRAF V600 melanoma cell lines ( Fig. 3D and E ) . Interestingly, BRAFi did not alter total MondoA protein expression ( Fig. 3E ) , indicating that BRAF V600 regulates the association of MONDOA with target gene promoters. To examine the mechanism of regulation of MYC and HIF-1α expression, we cotreated melanoma cells with vemurafenib and the proteasome inhibitor bortezomib. Bortezomib limited the effect of vemurafenib on HIF-1α protein expression; thus, BRAF V600 suppresses MYC and HIF1A transcription and HIF-1α degradation (Supplementary Fig. S10 ). Importantly, we confi rmed altered expression of these transcription factors in clinical melanoma specimens after BRAFi treatment. Although overall changes in HIF-1α and MYC expression did not reach statistical signifi cance, their expression was clearly decreased EOT and restored after progression in a subset of patient biopsies. In the cases of MYC and HIF1A , regional microenvironmental and hypoxic variability would signifi cantly affect gene expression, making it diffi cult to gain an accurate representation of mRNA expression from a small biopsy. We also observed that TXNIP mRNA expression was consistently and signifi cantly increased from baseline during treatment with a BRAFi ( P = 0.002) and decreased as compared with on-treatment expression levels ( P = 0.016) after disease progression ( Fig. 3F and Supplementary Fig. S5A-S5F ). Moreover, biopsies from patients who experienced stable disease or a partial response to BRAFi (RECIST criteria) demonstrated signifi cantly greater increases in TXNIP mRNA levels compared with biopsies from patients who experienced disease progression ( Fig. 3G ; P = 0.02), indicating the potential importance of TXNIP for responses to BRAF inhibition.
To examine regulation of glucose metabolism by MONDOA, MYC, and HIF-1α directly, each transcriptional regulator was targeted with siRNAs. Knockdown of MYC or HIF-1α phenocopied the inhibitory effect of BRAF knockdown on glucose uptake and cell proliferation, whereas MONDOA knockdown signifi cantly increased basal glucose uptake in melanoma cells ( Fig. 4A-C ) . This confi rms that MYC and HIF-1α promote glucose uptake, whereas MONDOA suppresses basal glucose uptake in BRAF V600 melanoma cells. Inhibition of gene expression using siRNAs showed that MONDOA suppresses basal GLUT1 and GLUT3 expression, HIF-1α promotes basal GLUT1 expression, and MYC promotes basal GLUT1 and HK2 expression while suppressing GLUT3 suppression ( Fig. 4D ) , demonstrating that each of these transcription factors controls a different subset of glycolytic targets. To address the role of this BRAF-regulated transcriptional network in responses to vemurafenib, we functionally modulated network components and examined the impact on vemurafenib responses. Suppression of glycolysis and cell proliferation by vemurafenib was partially reversed by siRNA-mediated MONDOA knockdown, activation of inducible c-Myc (MycER), or by exposure to hypoxia (that causes HIF-1α stabilization) in BRAF V600 melanoma cells ( Fig. 4E-M ) . This involved restored GLUT1/3 expression after siRNA-mediated MONDOA knockdown, GLUT1 expression by hypoxia, and HK2/GLUT1 expression by MYC overexpression in the presence of vemurafenib in WM266.4 BRAF V600 melanoma cells.
DISCUSSION
Recent reports have shown a link between BRAF V600 and glycolysis in both in vitro and in vivo models of cancer and in a clinical setting ( 8, 9 , 12 , 17 , 21 ) . Importantly, BRAFi has been shown to suppress glucose uptake in melanoma cells and xenografts ( 13 , 16 ) and in patient tumors ( 10 , 15 , 17, 18 ) . Here, we show that vemurafenib suppresses glycolysis in BRAF V600 melanoma cells independently of cell-cycle progression or cell death. In some cases, small reductions in the rate of oxphos occur in response to vemurafenib; however, these changes are only very modest and do not occur in all vemurafenib cell lines. Conversely, inhibition of glucose uptake signifi cantly correlated with vemurafenib sensitivity, indicating that the degree of ERK pathway output profoundly infl uences the magnitude of glucose uptake in melanoma cells. Expression of HK2 and GLUT1/3 was signifi cantly and consistently decreased in BRAF V600 melanoma cells in response to BRAF inhibition, and this is likely to underlie vemurafenibmediated suppression of glycolysis. Consistent with a role for glycolysis in cell survival, we describe dependence on glucose availability and expression of the glycolytic machinery for melanoma cell proliferation. Importantly, expression of SLC2A1, SLC2A3 , or HK2 mRNA was suppressed in melanoma biopsies from patients treated with the BRAFi dabrafenib or vemurafenib and, in some cases, was restored after disease progression. Thus, our data signifi cantly expand on the current understanding of BRAF V600 -driven glucose metabolism and suggest a possible role for glycolysis in responses and resistance of melanoma to BRAF-targeted therapies.
On the basis of the restoration of SLC2A1, SLC2A3 , or HK2 mRNA expression in some patient biopsies, we examined glycolysis in vemurafenib-resistant melanoma cells. Resistance to vemurafenib develops clinically after a median of 5 to 8 months ( 14 , 21 ) and poses a signifi cant challenge for the clinical management of BRAF V600 melanoma. Vemurafenib-resistant melanoma cells exhibited restored MEK-ERK activation, cell proliferation, HK2 and GLUT1/3 expression, and glucose uptake. Therefore, we determined whether the dependency of melanoma cells on glycolysis could be exploited to overcome vemurafenib resistance. We used the PDK inhibitor DCA that causes downstream reactivation of PDHE1α, thereby increasing pyruvate entry into the mitochondrial citric acid cycle/oxphos and suppressing glycolysis ( 19 ) . DCA restored vemurafenib sensitivity in melanoma cells that display BRAFi resistance via NRAS activation. This agrees with a recent study demonstrating that short hairpin RNAs (shRNA) targeting PDK1 synergize with BRAF inhibition in transformed human melanocytes and melanoma cells to suppress cell development of more-specifi c inhibitors of PDK1 with morefavorable pharmacokinetic profi les and fewer toxicities is currently under way ( 29 ) .
To investigate the mechanism by which BRAF V600 regulates glycolysis, we conducted gene expression arrays to identify putative glycolysis-regulating BRAF targets. We identifi ed a network of transcription factors, including MONDOA, HIF-1α, and MYC, which is tightly regulated by BRAF V600 . Expression of these transcription factors is altered by vemurafenib treatment in BRAF V600 melanoma cells and, importantly, in clinical melanoma specimens. Notably, the consistent modulation of TXNIP expression after BRAFi treatment and disease progression in melanoma biopsies indicates that MONDOA is a therapeutically important target of mutant BRAF that is likely to play an important role in the suppression of FDG uptake in the context of BRAF -mutant melanoma observed in patients.
We have also established the functional importance of this transcriptional network for BRAF V600 -driven glycolysis and melanoma cell proliferation. Stabilization of HIF-1α and upregulation of MYC expression has been demonstrated in a huge range of cancers, including melanomas, and regulation of HIF-1α and MYC expression by the RAF-MEK-ERK pathway has been previously described ( 31, 32 ) . We found that expression of MYC and HIF-1α is required for maintenance of basal glucose uptake in melanoma cells. Conversely, although regulation of MONDOA by oncogenic signaling pathways has been established ( 28 ) , the role of MONDOA in tumorigenesis is unclear. We show, for the fi rst time, that MONDOA is regulated by BRAF V600 and suppresses basal glucose uptake in melanoma cells. Furthermore, inhibition of MYC and HIF-1α and activation of MONDOA suppression is critical for metabolic and proliferative responses to vemurafenib.
Recently, Kaplon and colleagues ( 29 ) demonstrated that PDH is critical for oncogene-induced senescence (OIS) induced by BRAF V600E in mouse melanocytes and that abrogation of PDH activity overcame BRAF V600E -induced OIS. This agrees with our observation that BRAF inhibition suppresses PDH activity in BRAF -mutant melanoma cells (evidenced by increased PDH phosphorylation). These observations suggest that regulation of energy metabolism plays a pivotal role important for tumor development, cell survival, and BRAFi responses in the context of BRAF -mutant melanoma.
Our fi ndings show striking reductions in glycolysis and small reductions in the rate of oxygen consumption as an early response to BRAFi (24-hour treatment). A recent study by Haq and colleagues ( 33 ) , examining later time points (72-hour treatment) and adaptation to BRAFi, demonstrated increased mitochondrial biogenesis and expression of oxphos genes in BRAFi-treated melanoma cells that was associated with increased PGC1α expression. These data are consistent with a model of early treatment response in which potent inhibition of ERK-MAPK pathway activity suppresses glycolysis followed by longer-term adaptive changes, including increased oxphos in cells surviving BRAF inhibition. Longterm BRAF inhibition and stimulation of oxphos associated with increased mitochondrial activity might occur as a mechanism to overcome the suppression of glycolysis by BRAF inhibition described herein. Consistent with this suggestion, Gopal and colleagues found that melanoma cell lines displaying de novo resistance to ERK-MAPK pathway inhibition have a high basal rate of oxphos and increased expression of oxphos genes compared with MEK inhibitor-sensitive cell lines, and that this is associated with high expression of PGC1α (Y. Gopal and M. Davies; personal communication). Taken together, these fi ndings indicate that sensitivity to ERK-MAPK pathway inhibitors in the context of melanoma may be defi ned by a reliance on glycolysis for survival, and that stimulation of oxphos by ERK-MAPK pathway inhibition or high basal oxphos is associated with de novo and early adaptation and acquired resistance to ERK-MAPK pathway inhibition. Collectively, these data suggest that the metabolic background of a BRAF-mutant melanoma could be pivotal for responses to BRAF inhibition.
In summary, we have demonstrated that mutant BRAF tightly regulates glycolysis independently of cell-cycle progression or cell death and shown that melanoma cells have a requirement for access to glucose and intact glycolytic machinery for their proliferation. The combination of vemurafenib with the glycolytic inhibitor DCA was shown to restore sensitivity to BRAF inhibition in NRAS-activated vemurafenib-resistant melanoma cells, not only demonstrating the importance of glycolysis for melanoma cell survival but also providing a proof-of-principle for the combination of targeted therapeutics such as vemurafenib with glycolysis inhibitors to prevent the emergence of drug resistance. Finally, we have identifi ed a network of glycolysis regulators that operate under the control of oncogenic BRAF V600 to modulate glucose uptake in melanoma cells and are altered in clinical melanoma biopsies early during BRAFi treatment and upon development of resistance to BRAFi. For the fi rst time, our data show that inhibition of glycolysis via this network is critical for the suppression of proliferation and glucose uptake induced by inhibition of oncogenic BRAF.
METHODS
See Supplementary Data for a full description of Methods.
Materials and Cells
Vemurafenib and its analog PLX4720 were provided by Plexxikon Inc. Sodium DCA was purchased from Sigma-Aldrich. PD-0332991 (PD991) was provided by Pfi zer Inc. HEK-293T, MALME-3M, COLO829, A375, SK-MEL-28, HT144, LOX-IMVI, SK-MEL-2, A2058, CHL1, and MeWo cells were purchased from the American Type Culture Collection and National Cancer Institute (NCI; Bethesda, MD). CO89 and D04-M1 cells were obtained from the Australasian Biospecimen Network-Oncology Cell Line Bank at the Queensland Institute of Medical Research (QIMR) . Individuality of the melanoma cell lines was confi rmed on early-passage cells by PCR based shorttandem repeat (STR) analysis using six STR loci, and this analysis was routinely performed to confi rm the identity of cell lines. M249, M249-AR4, and M376 cell lines were a gift from Dr. Antoni Ribas (Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA). All melanoma cell lines were maintained in RPMI-1640 containing 10% FBS, 2 mmol/L L -alanyl-L -glutamine, 1% penicillin/streptomycin, and 250 ng/mL amphotericin B in a 37°C humidifi ed, 5% CO 2 incubator. The BRAF and NRAS mutation status of all cell lines has been reported previously ( 34, 35 ) and is described in Supplementary Table S3 ] of greater than 1 μmol/L were considered to be vemurafenib-resistant. The M249 cell line is a BRAF V600E cell line, whereas the M249-AR4 cell line was derived from M249 cells by long-term culture in vemurafenib and was shown to have developed an NRAS mutation ( 22 ) . The M376 cell line was derived from a patient tumor after relapse on vemurafenib therapy and was also shown to harbor an NRAS mutation ( 22 ) .
Analysis of Bioenergetics Using the Seahorse XF24 Extracellular Flux Analyzer
All extracellular fl ux analyses were performed using the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Seahorse XF24 V7 24-well plates were seeded at 5 × 
Microarray Experiments

A375 BRAF
V600E human melanoma cells were treated with 3 μmol/L vemurafenib or vehicle [0.1% dimethyl sulfoxide (DMSO)] for 24 hours, after which RNA was extracted ( n = 3). Whole-transcript sense target preparation and labeling (using the GeneChip WT Terminal Labeling and Controls and Ambion WT Expression Kits), hybridization to Affymetrix GeneChip 1.0 ST human gene arrays, and array scanning were completed by The Ramaciotti Centre Microarray Service of the University of New South Wales (Sydney, NSW, Australia). Data analysis is described in the Supplementary Methods. Melanoma cell line microarray data have been deposited in The Gene Expression Omnibus of the National Center for Biotechnology Information (accession number GSE42872).
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